Jazz Pharmaceuticals, Inc. will unveil its latest earnings on Monday, February 27, 2012. Jazz Pharmaceuticals is a specialty pharmaceutical company, which is focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.
Jazz Pharmaceuticals, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of $1.01 per share, a rise of 80.4% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.02. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.01 during the last month. Analysts are projecting profit to rise by 159% versus last year to $3.16.
Past Earnings Performance: Last quarter, the company beat estimates by 3 cents, coming in at net income of 87 cents a share versus the estimate of profit of 84 cents a share. It marked the fourth straight quarter of beating estimates.
Investing Insights: Warren Buffett Trashes Gold, But What About Silver?
Wall St. Revenue Expectations: Analysts are projecting a rise of 51.5% in revenue from the year-earlier quarter to $80.8 million.
Analyst Ratings: Analysts are high on the stock, with five analysts rating it as a buy, none rating it as a sell and none rating it as a hold.
A Look Back: In the third quarter, profit rose more than twofold to $32.5 million (69 cents a share) from $13.2 million (32 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 63.8% to $73.3 million from $44.8 million.
Key Stats:
The company has enjoyed double-digit year-over-year percentage revenue growth for the past four quarters. Over that span, the company has averaged growth of 51.8%, with the biggest boost coming in the most recent quarter when revenue rose 63.8% from the year earlier quarter.
Stock Price Performance: Between November 22, 2011 and February 21, 2012, the stock price rose $9.48 (25.3%), from $37.43 to $46.91. The stock price saw one of its best stretches over the last year between June 13, 2011 and June 23, 2011, when shares rose for nine straight days, increasing 19% (+$5.10) over that span. It saw one of its worst periods between May 9, 2011 and May 17, 2011 when shares fell for seven straight days, dropping 11.1% (-$3.39) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories:
Do Investors Love or Hate These 5 Retailers After Earnings?>>
Will Higher Gas Prices Derail the Recovery?>>
Gold and Silver Surge After Greece Bailout Deal>>
To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com
To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com
1 comment